Abstract
BACKGROUND: Serum cystatin C (sCysC) and urinary cystatin C (uCysC) are potential biomarkers for early detection of chronic kidney disease (CKD) in cats. An in-depth clinical validation is required. OBJECTIVES: To evaluate CysC as a marker for CKD in cats and to compare assay performance of the turbidimetric assay (PETIA) with the previously validated nephelometric assay (PENIA). ANIMALS: Ninety cats were included: 49 CKD and 41 healthy cats. METHODS: Serum CysC and uCysC concentrations were prospectively evaluated in cats with CKD and healthy cats. Based on plasma exo-iohexol clearance test (PexICT), sCysC was evaluated to distinguish normal, borderline, and low GFR. Sensitivity and specificity to detect PexICT < 1.7 mL/min/kg were calculated. Serum CysC results of PENIA and PETIA were correlated with GFR. Statistical analysis was performed using general linear modeling. RESULTS: Cats with CKD had significantly higher mean ± SD sCysC (1.4 ± 0.5 mg/L) (P
Author supplied keywords
Cite
CITATION STYLE
Ghys, L. F. E., Paepe, D., Lefebvre, H. P., Reynolds, B. S., Croubels, S., Meyer, E., … Daminet, S. (2016). Evaluation of Cystatin C for the Detection of Chronic Kidney Disease in Cats. Journal of Veterinary Internal Medicine, 30(4), 1074–1082. https://doi.org/10.1111/jvim.14256
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.